Grimes & Company, Inc. Iovance Biotherapeutics, Inc. Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
A detailed history of Grimes & Company, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 33,625 shares of IOVA stock, worth $376,263. This represents 0.01% of its overall portfolio holdings.
Number of Shares
33,625
Previous 33,375
0.75%
Holding current value
$376,263
Previous $267,000
17.98%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding IOVA
# of Institutions
321Shares Held
240MCall Options Held
1.27MPut Options Held
1.68M-
Vanguard Group Inc Valley Forge, PA26MShares$290 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY25.9MShares$290 Million6.02% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$269 Million28.39% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$238 Million0.0% of portfolio
-
State Street Corp Boston, MA12.6MShares$141 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.77B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...